Aleix Prat
Aleix Prat
Hospital Clinic
Verified email at - Homepage
Cited by
Cited by
Comprehensive molecular portraits of human breast tumours
Cancer Genome Atlas Network
Nature 490 (7418), 61, 2012
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
A Prat, JS Parker, O Karginova, C Fan, C Livasy, JI Herschkowitz, X He, ...
Breast cancer research 12 (5), 1-18, 2010
Deconstructing the molecular portraits of breast cancer
A Prat, CM Perou
Molecular oncology 5 (1), 5-23, 2011
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised …
E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ...
The lancet oncology 18 (9), 1274-1284, 2017
4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)
F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ...
Annals of Oncology 29 (8), 1634-1657, 2018
Prognostic significance of progesterone receptor–positive tumor cells within immunohistochemically defined luminal A breast cancer
A Prat, MCU Cheang, M Martín, JS Parker, E Carrasco, R Caballero, ...
Journal of clinical oncology 31 (2), 203, 2013
Clinical implications of the intrinsic molecular subtypes of breast cancer
A Prat, E Pineda, B Adamo, P Galván, A Fernández, L Gaba, M Díez, ...
The Breast 24, S26-S35, 2015
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
S Li, D Shen, J Shao, R Crowder, W Liu, A Prat, X He, S Liu, J Hoog, C Lu, ...
Cell reports 4 (6), 1116-1130, 2013
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer
A Prat, B Adamo, MCU Cheang, CK Anders, LA Carey, CM Perou
The oncologist 18 (2), 123, 2013
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer …
MJ Ellis, VJ Suman, J Hoog, L Lin, J Snider, A Prat, JS Parker, J Luo, ...
Journal of Clinical Oncology 29 (17), 2342, 2011
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ...
Cancer discovery 2 (11), 1036-1047, 2012
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models
X Zhang, S Claerhout, A Prat, LE Dobrolecki, I Petrovic, Q Lai, MD Landis, ...
Cancer research 73 (15), 4885-4897, 2013
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
RRL Bastien, Á Rodríguez-Lescure, MTW Ebbert, A Prat, B Munárriz, ...
BMC medical genomics 5 (1), 1-12, 2012
USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma
PJA Eichhorn, L Rodón, A Gonzàlez-Juncà, A Dirac, M Gili, ...
Nature medicine 18 (3), 429-435, 2012
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ...
Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R Dienstmann, J Rodon, A Prat, J Perez-Garcia, B Adamo, E Felip, ...
Annals of oncology 25 (3), 552-563, 2014
Practical implications of gene-expression-based assays for breast oncologists
A Prat, MJ Ellis, CM Perou
Nature reviews Clinical oncology 9 (1), 48, 2012
Defining the cellular precursors to human breast cancer
PJ Keller, LM Arendt, A Skibinski, T Logvinenko, I Klebba, S Dong, ...
Proceedings of the National Academy of Sciences 109 (8), 2772-2777, 2012
How many etiological subtypes of breast cancer: two, three, four, or more?
WF Anderson, PS Rosenberg, A Prat, CM Perou, ME Sherman
Journal of the National Cancer Institute 106 (8), dju165, 2014
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
JC Harrell, A Prat, JS Parker, C Fan, X He, L Carey, C Anders, M Ewend, ...
Breast cancer research and treatment 132 (2), 523-535, 2012
The system can't perform the operation now. Try again later.
Articles 1–20